Drug Discovery World

SEPTEMBER 6, 2022

Biopharmaceutical company Sosei Group received both Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan. Licensing Deal of the Year recognises deals that were closed during 2021. Licensing Deal of the Year recognises deals that were closed during 2021.

Licensing 130

Licensing Licensing Treatment Trials 130

Drug Discovery World

FEBRUARY 20, 2024

Licensing for human use Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Vaccine 130

Vaccine Immune Response Licensing Licensing 130

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

DECEMBER 1, 2020

02, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial statements. MARSEILLE, France, Dec. . .

Cell Biology 52

Cell Biology Clinical Trials Licensing Licensing 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Pfizer and BioNTech completed the rolling submission of the BLA in May 2021.

Licensing 52

Licensing Licensing Vaccine FDA 52

Drug Discovery World

AUGUST 4, 2023

Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021. GA is a progressive, irreversible retinal disease and one of the leading causes of blindness in people over 65 years of age.

Licensing 130

Licensing Licensing Drugs Disease 130

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — ImaginAb Inc. , a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Few details of the deal were disclosed in the announcement. A second liver biopsy will be performed after 18 months.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

Drug Discovery World

JULY 11, 2023

A first programme, BMS-986419 or EVT8683, targeting eIF2b, was in-licensed by BMS in September 2021, following the successful filing of an IND application with the FDA and has proceeded into clinical Phase I trials. The partnership has already been successful in generating a pipeline of discovery and pre-clinical-stage programmes.

Licensing 189

Licensing Licensing Drugs Disease 189

The Pharma Data

MARCH 2, 2021

and Shionogi Limited as shareholders, today announced the presentation of 16 sponsored abstracts from its diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2021), being held virtually 6-10 March.

Treatment 52

Treatment Pharmacokinetics Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB :s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed. The Annual General Meeting will be held on April 29, 2021 in Lund, Sweden. LUND, Sweden , Dec. Chairman of the Nomination Committee.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

DECEMBER 13, 2020

The FDA also recommended that Gamida Cell generate additional manufacturing-related data prior to requesting a pre-Biologics License Application (BLA) meeting. With this clarity, we look forward to proceeding towards a full BLA submission in the second half of 2021. chief executive officer of Gamida Cell. About Omidubicel.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

JANUARY 11, 2021

11, 2021 23:59 UTC. a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

Drug Discovery World

JULY 2, 2024

OECD data places Switzerland second in the world for biotechnology R&D intensity 1 , and in 2021, the country had the seventh largest share of the global biotech market 2.

Science 147

Science Drugs Clinical Trials Licensing 147

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). The transaction is expected to close in the second quarter of 2021. Biogen Inc. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. Source link:[link].

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

The Pharma Data

JULY 29, 2021

today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company. “We Reports Second Quarter Revenues of $11.7 and Non-GAAP EPS of $1.93 board chair and chief executive officer, Bristol Myers Squibb.

International 52

International Production Licensing Licensing 52

Drug Discovery World

JANUARY 31, 2024

Onward Therapeutics licensed the exclusive worldwide rights of development, manufacture, and commercialisation of OT-A201 from Biomunex Pharmaceuticals, a biopharmaceutical company discovering and developing bi- and multi-specific antibodies, in February 2021.

Clinical Trials 130

Clinical Trials Trials Treatment Pharmacokinetics 130

Drug Discovery World

OCTOBER 11, 2023

Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

MAY 3, 2023

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021.

Licensing 130

Licensing Licensing Clinical Development Therapies 130

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. As a result, we expect a 50-60% year-over-year Parsabiv sales decline in 2021.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

JANUARY 5, 2021

Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged. To accommodate the delay caused by these unforeseen circumstances, Targovax has granted to IOVaxis an extension to the license option period by 3 months.

Licensing 40

Licensing Licensing Vaccine Clinical Development 40

The Pharma Data

JANUARY 24, 2021

Quercis plans to initiate two Phase 3 clinical trials for the prevention of venous thromboembolism (VTE) in pancreatic cancer and glioblastoma patients in the first half of 2021 and will pursue U.S. ZUG, Switzerland , Jan. Chief Medical Officer of Quercis Pharma.

Licensing 40

Licensing Licensing Clinical Trials Medical Schools 40

The Pharma Data

MAY 4, 2021

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS. Tue, 05/04/2021 – 06:45. Tuesday, May 04, 2021 – 06:45am. <!–*/. First-Quarter 2021 Revenues of $14.6 First-Quarter 2021 Reported Diluted EPS (1) of $0.86, Adjusted Diluted EPS (2) of $0.93. Anonymous (not verified). –*/. <!–*/.q4default.bwalignc

Vaccine 40

Vaccine Production FDA Biosimilars 40

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. The information contained in this release is as of May 7, 2021. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 30, 2020

Food and Drug Administration (FDA), noted in December 2020 that he expected the pandemic could “effectively” be ended in 2021 with the launch of the Pfizer-BioNTech and Moderna vaccines. One way or the other, Biogen’s aducanumab for Alzheimer’s disease is likely to be a big story in 2021. Now that in the U.S. Now that in the U.S.

Vaccine 52

Vaccine FDA Trials Therapies 52

Drug Discovery World

APRIL 6, 2023

In Scotland, it has been available for these patients since July 2021 and has also been available for men with advanced, hormone-relapsed prostate cancer whose tumours have mutations in BRCA1 or BRCA2, since October 2021.

Clinical Trials 130

Clinical Trials Licensing Licensing Treatment 130

Drug Discovery World

JANUARY 13, 2023

These data will be shared with the FDA as part of the agency’s ongoing review of the Biologics License Application (BLA) of Roctavian. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec in March 2021. .

Therapies 130

Therapies FDA Licensing Licensing 130

The Pharma Data

MAY 18, 2021

Leverkusen, May 12, 2021 – The Bayer Group had a successful start to 2021. We’re seeing a good operational performance overall, but we were impacted by negative currency effects as expected,” said CEO Werner Baumann when the quarterly statement for the first quarter of 2021 was published on Wednesday. to 12.328 billion euros.

Science 40

Science Pharmaceuticals Production Marketing 40

The Pharma Data

MAY 6, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) authorized on May 10 , 2021. Pfizer Inc. This is the only COVID-19 vaccine authorized for this age group in the U.S.

Licensing 52

Licensing Licensing FDA Approval FDA 52

The Pharma Data

AUGUST 6, 2020

AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. That has changed. Financial terms were not disclosed.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

MARCH 25, 2022

Food and Drug Administration (FDA) has extended the review of the supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion-dependent (NTD) beta thalassemia to June 27, 2022. in November 2021. in November 2021. in November 2021.

Licensing 52

Licensing Licensing Drugs FDA 52

Drug Discovery World

SEPTEMBER 21, 2022

The combination treatment for this indication was approved by the US Food and Drug Administration in 2021 and gained a positive opinion from the CHMP earlier this year. Up to 210 in 100,000 people in Europe live with SLE and 40-60% of those are at risk of developing LN during their lifetime. .

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

AUGUST 23, 2022

If approved, ASTX727 would be the first and only oral hypomethylating agent licensed in the European Economic Area (EEA) for the initial treatment of adults with AML who are ineligible for intensive chemotherapy, offering a potentially more convenient treatment regimen. . References . ?

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

Drug Patent Watch

FEBRUARY 3, 2021

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve….

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

The Pharma Data

JANUARY 9, 2021

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year. 10, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. . 2021 FINANCIAL FORECAST. .

Government 52

Government Vaccine Production Licensing 52